Credit Suisse Downgrades Esperion Therapeutics To Neutral

Credit Suisse downgraded

from Outperform to Neutral. The price target for Esperion Therapeutics has been lowered from $130.00 to $86.00. Esperion Therapeutics shares have gained 433.75 percent over the past 52 weeks, while the S&P 500 index has surged 8.40 percent in the same period. Esperion Therapeutics' shares fell 1.82 percent to $79.50 in pre-market trading.